How does sharewise work?
Discuss
Discuss and share predictions for your favorite stocks in the forum. Let your opinion be heard
Show moreTop Buy/Sell (This Month)
| Security | Price | Target price |
|---|---|---|
| Microsoft Corp. | €434.00 | €500.91 |
| Amazon.com Inc. | €236.25 | €258.42 |
| Advanced Micro Devices Inc. | €424.75 | €523.14 |
| Security | Price | Target price |
|---|---|---|
| Clorox Co. | €91.64 | €91.19 |
| Western Union Co. | €6.22 | €6.07 |
| Nike Inc. B | €36.44 | €64.16 |
New Top predictions since last week
| Prediction | User | Perf. (%) |
|---|---|---|
| B Insmed Inc. | BiotechBee | 33.95% |
| B DroneShield Ltd | robertinio | 30.23% |
| B Applied Optoelectronics Inc. | mixitrader | 27.20% |
| Prediction | User | Perf. (%) |
|---|---|---|
| S Pantaflix AG | blaugold | -12.57% |
| S Best Buy Co. | Bank of America Co. | -6.79% |
| S Akanda Corp. | Lokrim | -6.55% |

sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Financial analysis of Broadridge
Broadridge Financial Solutions (BR.US) - FY2026 Annual Report
Broadridge appears to be experiencing a period of notably strong financial performance, with revenue reaching $7.48 billion and net income climbing to $1.12 billion. The company’s trajectory seems to be one of consistent expansion, with margins that have broadened steadily over the past five years.
The most striking development may lie in the profitability metrics. While revenue growth of 8.5% year-over-year reflects a healthy pace, the jump in net income of nearly 34% stands out, far outpacing revenue growth. This suggests significant operating leverage is being realized. The net margin expanded to over 15%, a considerable step up from the 12.2% seen just a year prior and from 9.4% in FY2022. This improvement appears to stem partly from modest operating margin gains, but a sharp swing in other non-operating income, which turned significantly positive, seems to have been a powerful contributor to the bottom-line surge. The reported return on equity of 39.6% is remarkably high, though it is notably amplified by a financial leverage ratio above 3x.
Portfolios of our members
DerAlmanach100000 3
When it comes to stocks, what is important for you?
Find stocks based on your criteria with our sharewise stock finder. All results are based on thousands of votes by our community
Pros and Cons of these stocks (New Predictions)
Deep Sea Minerals Corp.
WKN: A420P7 / Name: Deep Sea Minerals Corp. / Stock / ? /
Pros
Cons
Palantir Technologies Inc.
WKN: A2QA4J / Symbol: PLTR / Name: Palantir Technologies / Stock / Large Cap /
Pros
Cons
Try sharewise+ and get hundreds more matching stocks
Sign up for free!Tops & Flops S&P 500
| Security | Price | Change(%) (%) |
|---|---|---|
| Paycom Software | €187.60 | 21.030% |
| Wynn Resorts Ltd | €87.55 | 10.510% |
| Motorola Solutions | €411.50 | 8.720% |
| Parker-Hannifin | €928.40 | 7.740% |
| Borgwarner Inc. | €57.78 | 7.650% |
| Security | Price | Change(%) (%) |
|---|---|---|
| Honeywell Aerospace Inc. | €135.94 | -23.790% |
| Applovin Corp. | €291.35 | -19.480% |
| Datadog Inc. | €199.00 | -19.430% |
| Axon Enterprise INC | €453.50 | -15.120% |
| Western Digital Corp. | €391.75 | -12.800% |
Courses
sharewise Introduction
Key figures for stocks
Predictions
Top News
iRhythm Technologies Q2 Earnings Call Highlights
Key Points
- Interested in iRhythm Technologies? Here are five stocks we like better.
- Strong Q2 performance: Revenue rose 20.1% year over year to $224.2 million, while adjusted EBITDA reached
Innodata Q2 Earnings Call Highlights
Key Points
- Interested in Innodata Inc.? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 58% year over year to $92.1 million, while adjusted EBITDA increased 92% to
INmune Bio Q2 Earnings Call Highlights
Key Points
- Interested in INmune Bio, Inc.? Here are five stocks we like better.
- Regulatory and manufacturing progress: INmune Bio plans to seek conditional U.K. approval for Ebstrocel in late
Inogen Q2 Earnings Call Highlights
Key Points
- Interested in Inogen, Inc? Here are five stocks we like better.
- Second-quarter revenue rose 3% to $95.1 million, with international sales up 15% and new products helping offset a 2%
indie Semiconductor Q2 Earnings Call Highlights
Key Points
- Interested in indie Semiconductor, Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 24% year over year to $64 million, exceeding the midpoint of guidance by $2
Why Gamers Find Playtime a Smarter Stress Relief Than Scrolling for Deals
Sun Life (SLF) Surpasses Q2 Earnings and Revenue Estimates
Sun Life (SLF) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.29 per share a year ago. These figures
The RealReal (REAL) Reports Q2 Loss, Beats Revenue Estimates
The RealReal (REAL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.13 per share a year ago. These figures are
Turtle Beach (TBCH) Reports Q2 Loss, Misses Revenue Estimates
Turtle Beach (TBCH) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.14 per share a year ago. These figures are
E.W. Scripps (SSP) Reports Q2 Loss, Misses Revenue Estimates
E.W. Scripps (SSP) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.12 per share a year ago. These figures are
Sprout Social (SPT) Surpasses Q2 Earnings and Revenue Estimates
Sprout Social (SPT) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.18 per share a year ago. These
News
The Real Reason Structured Game-Based Finance Simulations Matter for Investors
Finanzmärkte im Wandel und wie neue digitale Dynamiken Investoren beeinflussen
ICU Medical Q2 Earnings Call Highlights
Key Points
- Interested in ICU Medical, Inc.? Here are five stocks we like better.
- Strong second-quarter performance: Revenue reached $548 million, with organic growth of 6%; adjusted EBITDA
ICF International Q2 Earnings Call Highlights
Key Points
- Interested in ICF International, Inc.? Here are five stocks we like better.
- Q2 revenue was essentially flat at $474.5 million, as 6.6% growth in non-federal markets offset a 9.5%
Hyperfine Q2 Earnings Call Highlights
Key Points
- Interested in Hyperfine, Inc.? Here are five stocks we like better.
- Revenue and system sales accelerated: Second-quarter revenue rose 45% year over year to $3.9 million, with 12
Health Catalyst Q2 Earnings Call Highlights
Key Points
- Interested in Health Catalyst, Inc.? Here are five stocks we like better.
- Q2 revenue reached $70.5 million, above guidance, while adjusted EBITDA of $9.9 million landed at the high
Esco Technologies (ESE) Q3 Earnings and Revenues Surpass Estimates
Esco Technologies (ESE) came out with quarterly earnings of $2.2 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $1.6 per share a year ago. These
Profound Medical (PROF) Q2 Earnings Surpass Estimates
Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.52 per share a year ago
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.59 per share a year ago. These figures
Contest
Still running
Heibel Ticker
sharewise sagt: Stephan Heibel ist ein langähriger Unterstützer und Autor der Wunschanalyse. Er betreibt meiner Meinung nach einen der besten Börsenbriefe. Es gibt eine kostenlose und eine Premium Variante.
Kostenlos ausprobierensharewise
Du findest das sharewise Projekt spannend und möchtest es unterstützen?
Mit einer
sharewise+-Mitgliedschaft
unterstützt du uns finanziell und bekommst zusätzliche Funktionalitäten freigeschalten.
Leeway
Die Analyse-Plattform Leeway untersucht mit KI-unterstützten Algorithmen aussagekräftige Zusammenhänge am Aktienmarkt. Anhand von vielen Millionen Datenpunkten finden die Algorithmen die Kennzahlen und Bewegungen, die nachweisbare Auswirkungen haben und Vorteile schaffen.
Kostenlos ausprobierensharewise
Du findest das sharewise Projekt spannend und möchtest es unterstützen?
Mit einer
sharewise+-Mitgliedschaft
unterstützt du uns finanziell und bekommst zusätzliche Funktionalitäten freigeschalten.










